Bookmarks
ICON9 Trial
Population Size
Not reported
Years
2018
Associated BioSamples
Serum
Tissue
Geographic coverage
United Kingdom
England
Lead time
Other
Summary
Collection of samples and data across the following diseases: Malignant tumour of ovary
Documentation
An international phase III randomised study to evaluate the efficacy of maintenance cediranib and olaparib combination therapy or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy
Dataset type
Health and disease
Dataset sub-type
Not applicable
Keywords
ICON9, Olaparib, UKCRC Tissue Directory, Cediranib, Malignant tumour of ovary, Cancer, Ovarian
Provenance
Image contrast
Not stated
Biological sample availability
Serum,Tissue
Details
Publishing frequency
Other
Version
1.0.0
Modified
08/10/2024
Citation Requirements
In Progress
Coverage
Start date
01/01/2018
Time lag
Variable
Geographic coverage
United Kingdom, England
Minimum age range
40
Maximum age range
150
Accessibility
Language
en
Controlled vocabulary
LOCAL
Format
In Progress
Data Access Request
Dataset pipeline status
Not available
Access rights
Please contact the publisher using Contact Point details provided
Time to dataset access
Other
Access request cost
Not specified
Access method category
Varies based on project
Data Controller
University College London